“For most of the U.S. companies, it's more about cost control than revenue growth. I think you'll see more of this the rest of the year until we start seeing pipeline products get to market.”
“A lot of people feel like they've missed it and the best days of the sector are behind it so why jump in when there's even a hint of medical cost trends going in the wrong direction.”
